Overview

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.

Phase:

Phase 2

Details

Lead Sponsor:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Treatments:

Analgesics, Opioid